Advanced Oncotherapy Plc (LON:AVO) is the topic of conversation when Hardman & Co Analyst Dr Martin Hall caught up with DirectorsTalk. Martin shares his thoughts on the latest interims, explains what AVO need to do in the short term to be on the road to profitability, the risks involved, trends in the proton therapy market and the key attractions potential investors should look at when considering AVO.
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy’s team “ADAM”, based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.
The company will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
